Carsten Brunn, Selecta Biosciences CEO

Has Se­lec­ta found a way around gene ther­a­py's de­liv­ery prob­lem? Take­da puts down $1B-plus to find out

While gene ther­a­pies were tra­di­tion­al­ly thought of as one-and-done treat­ments, sci­en­tists now see a ben­e­fit in re­dos­ing pa­tients down the road. The on­ly prob­lem? Some pa­tients mount an im­mune re­sponse to the ade­no-as­so­ci­at­ed virus­es (AAV) used to de­liv­er the ther­a­pies.

It’s one of gene ther­a­py’s most press­ing is­sues, and a raft of com­pa­nies are work­ing on non-vi­ral de­liv­ery meth­ods to get around it. But Se­lec­ta Bio­sciences thinks it’s found an­oth­er way to tamp down the body’s im­mune re­sponse — and Take­da is ready to dole out more than $1 bil­lion to get in on the ac­tion.

Take­da is putting down an undis­closed amount up­front and more than $1.1 bil­lion in biobucks to li­cense Se­lec­ta’s Imm­TOR plat­form for its two undis­closed gene ther­a­pies for lyso­so­mal stor­age dis­or­ders, the com­pa­nies said on Mon­day.

Se­lec­ta’s plat­form makes use of a biodegrad­able nanopar­ti­cle that en­cap­su­lates the im­muno­sup­pres­sive drug ra­pamycin, and is de­signed to be giv­en in con­junc­tion with gene ther­a­pies to in­duce anti­gen-spe­cif­ic im­mune tol­er­ance.

“Most of the safe­ty events [in the field] have been seen at the high­er dos­es,” CEO Carsten Brunn told End­points News. “So if you can give a low­er dose or mul­ti­ple low­er dos­es, that could re­al­ly trans­form the treat­ment reg­i­men.”

Brunn de­clined to com­ment on Take­da’s spe­cif­ic tar­gets or their stage of de­vel­op­ment. But he did say that Se­lec­ta filed an IND last week for its lead in-house gene ther­a­py pro­gram, a treat­ment for methyl­malonic acidemia (MMA) called MMA-101. Right be­hind that pro­gram is a treat­ment for or­nithine tran­scar­bamy­lase de­fi­cien­cy (OTCD), which Brunn said should be ready for an IND by the end of next year.

Back in April, AskBio hit the ex­it on a li­cens­ing deal for MMA-101 af­ter find­ing fault with a con­tract man­u­fac­tur­er’s work. Brunn said the prob­lem was a fill-fin­ish is­sue, which has since been re­solved.

Se­lec­ta is far from alone in the hunt for gene ther­a­py 2.0. An­jar­i­um Bio­sciences and GenEd­it both un­veiled hefty Se­ries A rounds last month to sup­port their non-vi­ral ap­proach­es. Glax­o­SmithK­line vet Bri­an McVeigh launched Code Bio­ther­a­peu­tics just a few months ago to find a non-vi­ral de­liv­ery method. And Gen­er­a­tion Bio closed a $230 mil­lion IPO last June to fund its pre­clin­i­cal push to treat dis­eases of the liv­er and reti­na.

“Se­lec­ta’s Imm­TOR plat­form is de­signed to mit­i­gate un­want­ed im­mune re­spons­es al­low­ing for re­dos­ing, which could have broad ap­plic­a­bil­i­ty across our gene ther­a­py pro­grams for a range of dis­eases,” Mad­hu Natara­jan, head of Take­da’s rare dis­eases drug dis­cov­ery unit, said in a state­ment.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'


Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

Rahul Singhvi, Resilience CEO

A Bob Nelsen start­up turns to Har­vard to help sharp­en its tech, in­spir­ing first spin­out

One of Bob Nelsen’s latest projects is headed to Harvard.

Resilience, a company started with the goal of establishing itself as a “one-stop-shop” for companies looking to scale manufacturing, including for hard-to-develop cell and gene therapies, is less than a year old. Friday, it announced a five-year R&D deal with Harvard University that includes $30 million to develop biologics, including vaccines, nucleic acids and cell and gene therapies.

John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)

Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

A year and a half after Chinese officials ordered BeiGene to stop selling Bristol Myers Squibb’s Abraxane in the wake of an alarming inspection of a US facility, the manufacturing issues at the root of the import suspension still appear unresolved.

And Bristol Myers wants to axe the Abraxane supply deal altogether.

But BeiGene, which is currently in arbitration proceedings against its Big Pharma partner, won’t let it off the hook so easily.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

Madhu Natarajan, Takeda rare disease development head

Drawn to the idea of turn­ing B cells in­to 'pro­tein fac­to­ries,' Take­da jumps in­to a mile­stone-heavy, $900M pact

Madhu Natarajan can trace his fascination with the idea of taking B cells and turning them into protein factories back 20 years, when he had his own lab at UT Southwestern. So when Natarajan, now the rare disease development head for Takeda, sat down for a meet-up with execs from Seattle-based Immusoft at the last in-person JP Morgan conference, they went straight into a brainstorming session.

“That B cells can take up residence and do what they do for a long time,” says Natarajan, pumping out proteins and “leveraging it into a therapeutic context,” hits his sweet spot for discovery deals. And he was deeply impressed by what he heard.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.